Combination of Nilotinib and Pegylated Interferon Alfa-2b Results in High Molecular Response Rates in Chronic Phase CML: Interim Results of the ALLG CML 11 Pinnacle StudyDavid T Yeung, On Behalf of the ALLG, David Kipp et al.|Blood|2018Cited by 8
Combination of Nilotinib and Pegylated Interferon Alfa-2B Results in High Rates of MR4.5 at 24 Months - Primary Analysis of the ALLG CML 11 Pinnacle StudyDavid T Yeung, On Behalf of the ALLG, Naranie Shanmuganathan et al.|Blood|2019Cited by 7
Pro-Active Dasatinib Dose Reduction Based on Trough Levels May Minimise Toxicity and Preserve Efficacy - Interim Analysis of the ALLG CML 12 Direct StudyDavid T Yeung, On Behalf of the ALLG, Andrew Grigg et al.|Blood|2019Cited by 3
P720: PROACTIVE DASATINIB DOSE REDUCTION IN THE ALLG CML 12 DIRECT STUDY BASED ON TROUGH LEVELS MINIMISE TOXICITY AND PRESERVE EFFICACYDavid T Yeung, Timothy P. Hughes, Andrew Grigg et al.|HemaSphere|2022Cited by 1
The <scp>PINNACLE</scp> study: A multicentre phase <scp>II</scp> trial of nilotinib in combination with pegylated interferon‐α2b in newly diagnosed chronic phase chronic myeloid leukaemiaDavid T. Yeung, the Australasian Leukaemia and Lymphoma Group, Andrew P. Grigg et al.|British Journal of Haematology|2025Cited by 1